

Technology Strategy Board

Driving Innovation

An introduction to the Technology Strategy Board

Dr Penny Wilson

Lead Specialist – the Detection & Identification of Infectious Agents

11 November 2011, St Anne's College, Oxford

The Technology Strategy Board

A national organisation promoting technology-enabled innovation...


for business benefit, economic growth, and quality of life

Investment Criteria

- Does the UK have the capability?
- Is there a large market opportunity?
- Is the idea ready?
- Can the Technology Strategy Board make a difference?



Continuity of Funding



Technology Strategy Board

Driving Innovation

Priority Themes

Sustainability

Energy

Built
Environment

Food

Transport

Healthcare

High Value Manufacturing

Digital Services

Advanced
Materials

ICT


Electronics,
Photonics and
Electrical
Systems

Biosciences

Development




Challenges:



The Detection and Identification of Infectious Agents Innovation Platform (1)

- Aims to:
 - create business opportunity and wealth in the UK
 - encourage the development and adoption of commercially viable diagnostic devices
 - reduce the mortality, morbidity and economic burden due to infectious agents in humans and animals
- Focused on point-of-care diagnostics



Technology Strategy Board

Driving Innovation

The Detection and Identification of Infectious Agents Innovation Platform (2)

- Supports Department of Health and Defra priorities
- Issues include: adoption, trans-disciplinary nature of diagnostics, regulatory, animal vs human...

- **First Competition**


Feasibility, Fast-track (pilot schemes) and Larger CR&D projects (STIs and HAIs)

- **Second series of competitions**


Sepsis I: Multi-pathogen detection and/or simple discrimination

Sepsis II: Advancing biomarker use in sepsis management

DIIA SBRI: Assessing the impact of near-patient testing




Devices should be fit for purpose



- Technology is only ever part of the solution.
- Consideration of the environment, infrastructure and patient care pathway is critical to successful adoption

Integrated Innovation TM



Clinically useful diagnostics

- A critical part of disease/health management
 - Decision making tools
 - Ideally predisposition, pre-clinical diagnosis, disease prevention
- Product specifications must be fit for purpose and consider:
 - ease of use, time to result, sensitivity, specificity, positive and negative predictive values, quality control, waste disposal and data capture and security
- Commercially viable
someone must pay!





DIIA SBRI: **Assessing the impact of near-patient testing**

Registration closed

Developed with NICE and BIVDA

The Challenge

- The NHS is a slow adopter of new technologies
- Impact data, in terms of cost, patient outcome and public health are rarely presented to decision makers.
- Clinical trials are designed for regulatory approval
- Incomplete data and a *lack of modelling tools* make it difficult to estimate the impact of new tests

What evidence is needed for assessment of new POC technologies?



Technology Strategy Board

Driving Innovation



A dream with
courage is
innovation...A
dream
without
courage is a
delusion

Thank you for your attention